2025
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
Bordeaux J, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, LeBoeuf N, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha A, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 39819674, DOI: 10.6004/jnccn.2025.0001.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesDermatofibrosarcoma protuberansClinical practice guidelinesNegative marginsFibrosarcomatous dermatofibrosarcoma protuberansRate of recurrenceSoft tissue sarcomasRecommended treatment optionPractice guidelinesCutaneous soft tissue sarcomasLocal recurrenceRadiation therapySurgical excisionAggressive variantSystemic treatmentInitial treatmentTissue sarcomasTreatment optionsLocal infiltrationIncreased riskRecurrenceMetastasisProtuberansMultidisciplinary teamNCCN
2024
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology.
Hodan R, Gupta S, Weiss J, Axell L, Burke C, Chen L, Chung D, Clayback K, Felder S, Foda Z, Giardiello F, Grady W, Gustafson S, Hagemann A, Hall M, Hampel H, Idos G, Joseph N, Kassem N, Katona B, Kelly K, Kieber-Emmons A, Kupfer S, Lang K, Llor X, Markowitz A, Prats M, Niell-Swiller M, Outlaw D, Pirzadeh-Miller S, Samadder N, Shibata D, Stanich P, Swanson B, Szymaniak B, Welborn J, Wiesner G, Yurgelun M, Dwyer M, Darlow S, Diwan Z. Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 695-711. PMID: 39689429, DOI: 10.6004/jnccn.2024.0061.Peer-Reviewed Original ResearchConceptsMultigene panel testingPathogenic/likely pathogenic variantsGenetic/Familial High-Risk AssessmentColon cancer screeningColon cancer riskHigh risk of cancerNCCN Clinical Practice GuidelinesClinical practice guidelinesRisk of cancerPanel testingHigh riskPathogenic variantsPeutz-Jeghers syndromeLynch syndromeCancer screeningDe-implementationCancer riskEndometrial cancerPTEN hamartoma tumor syndromeHigh-risk assessmentPractice guidelinesHamartoma tumor syndromePeutz-JeghersNCCN guidelinesCHEK2Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Streiff M, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R, Fertrin K, Fogerty A, Crestani N, Gangaraju R, Rojas-Hernandez C, Goldhaber S, Ibrahim I, Kubal T, Leavitt A, Lim M, Mann J, Mantha S, Morton C, Nester A, O'Brien A, Ortel T, Pine A, Pishko A, Ranade M, Salmasi A, Schaefer J, Williams E, Wool G, Wun T, Montgomery S, Nguyen J, Freedman-Cass D, Sliker B. Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 483-506. PMID: 39236759, DOI: 10.6004/jnccn.2024.0046.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesNCCN guidelinesClinical practice guidelinesVenous thromboembolismVenous thromboembolic diseaseNCCN panelCancer-associated venous thromboembolismInternal medicinePractice guidelinesMedical oncologyThromboembolic diseaseTreatment of venous thromboembolismNCCNLife-threatening conditionMultidisciplinary effortRecommended treatment optionGuidelinesOncologyAdult patientsTreatment optionsInterventional radiologyDiverse subtypesCancerPatientsPreventionNeuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Bagatell R, Park J, Acharya S, Aldrink J, Allison J, Alva E, Arndt C, Benedetti D, Brown E, Cho S, Church A, Davidoff A, Desai A, DuBois S, Fair D, Farinhas J, Harrison D, Huang F, Iskander P, Kreissman S, Macy M, Na B, Pashankar F, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Schonfeld R, Hang L. Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 413-433. PMID: 39151455, DOI: 10.6004/jnccn.2024.0040.Peer-Reviewed Original ResearchConceptsNCCN guidelinesNCCN Clinical Practice GuidelinesClinically heterogeneous diseaseExtracranial solid tumorTreatment of neuroblastomaClinical practice guidelinesNeuroblastoma panelRadiation oncologistsNCCN Member InstitutionsSolid tumorsHeterogeneous diseaseConsensus recommendationsPediatric oncologistsNeuroblastomaNCCNGroup of representativesRisk classificationEvidence-basedMultidisciplinary groupPractice guidelinesOncologistsMember institutionsGuidelinesTreatmentTumorColon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Benson A, Venook A, Adam M, Chang G, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber J, Sofocleous C, Tavakkoli A, Willett C, Wu C, Gurski L, Snedeker J, Jones F. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22 PMID: 38862008, DOI: 10.6004/jnccn.2024.0029.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerNCCN Clinical Practice GuidelinesSystemic therapy optionsGoal of therapyClinical practice guidelinesNCCN guidelinesToxicity profileTherapy optionsColon cancerMutation profilesActive drugCancer deathDiagnosed cancerCancerConstituent drugsTherapyPractice guidelinesNCCNDrugTumorColorectalGuidelinesUnited StatesOncologyVulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Gaillard S, Giuntoli R, Glaser S, Holmes J, Howitt B, Kendra K, Lea J, Lee N, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Rodabaugh K, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington S, Wyse E, Zanotti K, McMillian N, Espinosa S. Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 117-135. PMID: 38503056, DOI: 10.6004/jnccn.2024.0013.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesVulvar cancerClinical practice guidelinesCell carcinomaHistologically squamous cell carcinomaSystemic therapy optionsSquamous cell carcinomaBasal cell carcinomaExtramammary Paget's diseasePractice guidelinesVerrucous carcinomaGynecologic malignanciesHuman papillomavirusVulvar neoplasiaTherapy optionsPaget's diseaseInflammatory conditionsRisk factorsCigarette smokingCarcinomaCancerIncreasing ageHistologyNCCNVulvar
2023
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Schmults C, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bordeaux J, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, Ho A, Lukens J, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha A, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 1181-1203. PMID: 37935106, DOI: 10.6004/jnccn.2023.0056.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBasal cell carcinomaNCCN Clinical Practice GuidelinesClinical practice guidelinesSkin cancerTreatment optionsPractice guidelinesBasal cell skin cancerPrevalent treatment optionPrevious medical therapyLimitation of functionBCC occurrenceMedical therapyRisk stratificationBCC developmentCell carcinomaCancerCommon formOncologyAnnual rateEstimated ratesGuidelinesKey playersSurgeryCarcinomaHigh frequencyMesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Ettinger D, Wood D, Stevenson J, Aisner D, Akerley W, Bauman J, Bharat A, Bruno D, Chang J, Chirieac L, DeCamp M, Dilling T, Dowell J, Durm G, Gettinger S, Grotz T, Gubens M, Hegde A, Lackner R, Lanuti M, Lin J, Loo B, Lovly C, Maldonado F, Massarelli E, Morgensztern D, Mullikin T, Ng T, Otterson G, Patel S, Patil T, Polanco P, Riely G, Riess J, Shapiro T, Singh A, Tam A, Tanvetyanon T, Yanagawa J, Yang S, Yau E, Gregory K, Hughes M. Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 961-979. PMID: 37673108, DOI: 10.6004/jnccn.2023.0045.Peer-Reviewed Original ResearchAdolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Bhatia S, Pappo A, Acquazzino M, Allen-Rhoades W, Barnett M, Borinstein S, Casey R, Choo S, Chugh R, Dinner S, Ermoian R, Fair D, Federman N, Folbrecht J, Gandhi S, Germann J, Goldsby R, Hayashi R, Huang A, Huang M, Jacobs L, Lee-Miller C, Link M, Livingston J, Lustberg M, Malogolowkin M, Oeffinger K, Pratilas C, Reed D, Skiles J, von Mehren M, Yeager N, Montgomery S, Hang L. Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 851-880. PMID: 37549914, DOI: 10.6004/jnccn.2023.0040.Peer-Reviewed Original ResearchConceptsYoung Adult OncologyAYA patientsAdult oncologyNCCN guidelinesNCCN Clinical Practice GuidelinesClinical practice guidelinesSupportive care servicesFertility counselingRisk factorsComprehensive carePractice guidelinesCare servicesPatientsOlder adultsOncologyCancerUnique needsGuidelinesAdolescentsBehavioral issuesDiagnosisCareAnal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Benson A, Venook A, Al-Hawary M, Azad N, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Hecht J, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber J, Sofocleous C, Stotsky-Himelfarb E, Tavakkoli A, Willett C, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 653-677. PMID: 37308125, DOI: 10.6004/jnccn.2023.0030.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesAnal carcinomaClinical practice guidelinesPrimary treatmentPractice guidelinesSquamous cell anal carcinomaCommon histologic formExtrapelvic metastatic diseaseMetastatic anal carcinomaSystemic therapy recommendationsAnal canal cancerCurative-intent treatmentAJCC staging systemNCCN guidelinesPerianal cancerMetastatic diseasePersistent diseaseSystemic therapySurgical treatmentMedical oncologyStaging systemOptimal treatmentClinical evaluationHistologic formsTherapy recommendationsThe Value and Process of Inclusion: Using Sensitive, Respectful, and Inclusive Language and Images in NCCN Content.
Freedman-Cass D, Fischer T, Alpert A, Obedin-Maliver J, Kunz P, Koh W, Carlson R. The Value and Process of Inclusion: Using Sensitive, Respectful, and Inclusive Language and Images in NCCN Content. Journal Of The National Comprehensive Cancer Network 2023, 21: 434-441. PMID: 37156485, DOI: 10.6004/jnccn.2023.7025.Peer-Reviewed Original ResearchConceptsCancer careEquitable cancer careEffective cancer careNCCN Clinical Practice GuidelinesClinical practice guidelinesOptimal oncology careRepresentation of diverse populationsCancer informationOncology careAnti-fat biasPractice guidelinesCareDiverse populationsNCCN guidelinesGoals of equityNCCNHigh-qualityGuidelinesInclusionSexual orientationInclusive languagePatientsNonstigmatizingIndividualsProfessional contentEsophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Ajani J, D'Amico T, Bentrem D, Cooke D, Corvera C, Das P, Enzinger P, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter W, Ilson D, Jalal S, Keswani R, Kim S, Kleinberg L, Klempner S, Lacy J, Licciardi F, Ly Q, Matkowskyj K, McNamara M, Miller A, Mukherjee S, Mulcahy M, Outlaw D, Perry K, Pimiento J, Poultsides G, Reznik S, Roses R, Strong V, Su S, Wang H, Wiesner G, Willett C, Yakoub D, Yoon H, McMillian N, Pluchino L. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 393-422. PMID: 37015332, DOI: 10.6004/jnccn.2023.0019.Peer-Reviewed Original ResearchConceptsEsophagogastric junction cancerSquamous cell carcinomaJunction cancerMetastatic diseaseSystemic therapyNCCN Clinical Practice GuidelinesEsophageal squamous cell carcinomaMajor global health problemBest supportive careManagement of recurrentMultidisciplinary team managementClinical practice guidelinesTreatment of patientsGlobal health problemMicrosatellite instability statusNCCN guidelinesPalliative managementSupportive careEsophagogastric junctionCell carcinomaLower esophagusEsophageal cancerHER2 statusTumor locationBiomarker testingUterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Chu C, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Giuntoli R, Han E, Holmes J, Howitt B, Lea J, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington S, Wyse E, Zanotti K, McMillian N, Aggarwal S. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 181-209. PMID: 36791750, DOI: 10.6004/jnccn.2023.0006.Peer-Reviewed Original ResearchConceptsUterine neoplasmsNCCN guidelinesNCCN Clinical Practice GuidelinesPure endometrioid carcinomasUterine cancer casesClinical practice guidelinesFemale genital tractMesenchymal sarcomaEndometrial histologyEndometrioid cancerCommon malignancyEndometrial carcinomaUncommon subtypeEndometrioid carcinomaUterine cancerGenital tractCancer casesPractice guidelinesCarcinomaNeoplasmsCancerGuidelinesAdenocarcinomaEndometriumSarcoma
2022
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gerds A, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George T, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kaesberg P, Kuykendall A, Madanat Y, McMahon B, Mohan S, Nadiminti K, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein B, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward D, Bergman M, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 1033-1062. PMID: 36075392, DOI: 10.6004/jnccn.2022.0046.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesMyeloproliferative neoplasmsClinical practice guidelinesEssential thrombocythemiaPolycythemia veraRisk stratificationManagement of myeloproliferative neoplasmsOverproduction of blood cellsPhiladelphia chromosome-negative myeloproliferative neoplasmsDiagnosis of myeloproliferative neoplasmsPractice guidelinesClonal blood disorderManagement of myelofibrosisCourse of treatmentSupportive care strategiesAssessment of symptomsNCCN guidelinesDiagnostic workupCare strategiesMultidisciplinary panelBlood disordersHeterogeneous groupSymptom statusBlood cellsNCCNThe Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients.
O'Shaughnessy J, Encarnacion C, O'Neal B, Wong J, Siuliukina N, Sanft T, Jankowitz R, Pegram M, Treuner K, Fox J. The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients. Journal Of Clinical Oncology 2022, 40: e12513-e12513. DOI: 10.1200/jco.2022.40.16_suppl.e12513.Peer-Reviewed Original ResearchBreast Cancer IndexExtended endocrine therapyLate distant recurrenceBreast cancer patientsRegistry studyEndocrine therapyDistant recurrenceClinicopathological factorsMedication adherenceCancer patientsHigh riskLower riskHormone receptor-positive breast cancer patientsReceptor-positive breast cancer patientsEarly-stage breast cancer patientsNCCN Clinical Practice GuidelinesLong-term clinical outcomesPositive breast cancer patientsAssociated clinicopathological factorsAdjuvant endocrine therapyNode-negative patientsNode-positive patientsPrognostic risk groupsClinical practice guidelinesRoutine clinical careNon-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 497-530. PMID: 35545176, DOI: 10.6004/jnccn.2022.0025.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNCCN Clinical Practice GuidelinesCell lung cancerClinical practice guidelinesLung cancerPractice guidelinesMetastatic non-small cell lung cancerMetastatic lung cancerNCCN guidelinesPrimary treatmentTargeted therapyActionable mutationsPatientsCancerSubsequent treatmentTherapyOncologyTreatmentGuidelinesImmunotherapyRelapseDiagnosisT-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 285-308. PMID: 35276674, DOI: 10.6004/jnccn.2022.0015.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaAnaplastic large cell lymphomaLarge cell lymphomaAnaplastic lymphoma kinaseCell lymphomaLymphoma kinaseTreatment of PTCLNCCN Clinical Practice GuidelinesAngioimmunoblastic T-cell lymphomaClinical practice guidelinesNon-Hodgkin lymphomaMature T cellsNCCN guidelinesLymphoproliferative disordersCommon subtypePractice guidelinesT cellsLymphomaHeterogeneous groupGuidelinesSubtypesDiagnosisOncologyKidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 71-90. PMID: 34991070, PMCID: PMC10191161, DOI: 10.6004/jnccn.2022.0001.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaStage IV renal cell carcinomaNCCN guidelinesKidney cancerTreatment selectionNCCN Clinical Practice GuidelinesAdvanced renal cell carcinomaSystemic therapy recommendationsFirst-line treatmentPre-existing comorbiditiesClinical practice guidelinesKidney cancer therapyRecommended regimensSystemic therapyRisk stratificationTumor histologyCell carcinomaTreatment recommendationsTherapy recommendationsRisk groupsPractice guidelinesCancer fociTherapy selectionCancer panelPatients
2021
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Janku F, Karmali R, Morgan D, Raldow AC, Stefanovic A, Tantravahi SK, Walkovich K, Zhang L, Bergman MA, Darlow SD. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2021, 19: 1277-1303. PMID: 34781268, DOI: 10.6004/jnccn.2021.0053.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHistiocytic neoplasmsNCCN Clinical Practice GuidelinesCommon histiocytic disorderRare hematologic disorderRosai-Dorfman diseaseTreatment of adultsClinical practice guidelinesErdheim-Chester diseaseLangerhans cell histiocytosisNCCN guidelinesSelect patientsSystemic therapyLymph nodesClinical presentationMild diseaseCell histiocytosisHematologic disordersHistiocytic disorderPractice guidelinesOptimal managementPatientsNeoplasmsSoft tissueDiseaseDisordersPediatric Hodgkin Lymphoma, Version 3.2021.
Flerlage J, Hiniker S, Armenian S, Benya E, Bobbey A, Chang V, Cooper S, Coulter D, Cuglievan B, Hoppe B, Isenalumhe L, Kelly K, Kersun L, Lamble A, Larrier N, Magee J, Oduro K, Pacheco M, Price A, Roberts K, Smith C, Sohani A, Trovillion E, Walling E, Xavier A, Burns J, Campbell M. Pediatric Hodgkin Lymphoma, Version 3.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 733-754. PMID: 34214968, DOI: 10.6004/jnccn.2021.0027.Peer-Reviewed Original ResearchConceptsPediatric Hodgkin lymphomaClassic Hodgkin lymphomaHodgkin's lymphomaNCCN Clinical Practice GuidelinesClinical practice guidelinesCurrent treatment regimensNCCN guidelinesRefractory settingSystemic therapyCurable formTreatment regimensPrinciples of pathologyDiagnostic evaluationLate effectsPractice guidelinesRadiation therapyTreatment efficacyLymphomaTherapyTreatmentGuidelinesRegimensWorkupCancerStaging
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply